Effects of Aspirin on Endothelial Function and Hypertension

Overview

Journal Curr Hypertens Rep

Specialty Cardiology & Vascular Diseases

Date 2016 Oct 28

PMID 27787837

Citations 19

Authors

Mikhail S Dzeshka

Alena Shantsila

Gregory Y H Lip

Affiliations

Soon will be listed here.

Abstract

Purpose Of Review: Endothelial dysfunction is intimately related to the development of various cardiovascular diseases, including hypertension, and is often used as a target for pharmacological treatment. The scope of this review is to assess effects of aspirin on endothelial function and their clinical implication in arterial hypertension.

Recent Findings: Emerging data indicate the role of platelets in the development of vascular inflammation due to the release of proinflammatory mediators, for example, triggered largely by thromboxane. Vascular inflammation further promotes oxidative stress, diminished synthesis of vasodilators, proaggregatory and procoagulant state. These changes translate into vasoconstriction, impaired circulation and thrombotic complications. Aspirin inhibits thromboxane synthesis, abolishes platelets activation and acetylates enzymes switching them to the synthesis of anti-inflammatory substances. Aspirin pleiotropic effects have not been fully elucidated yet. In secondary prevention studies, the decrease in cardiovascular events with aspirin outweighs bleeding risks, but this is not the case in primary prevention settings. Ongoing trials will provide more evidence on whether to expand the use of aspirin or stay within current recommendations.

Citing Articles

Association of early aspirin use with 90-day mortality in patients with sepsis: an PSM analysis of the MIMIC-IV database.

Huang C, Tong Q, Zhang W, Pan Z Front Pharmacol. 2025; 15():1475414.

PMID: 39850571 PMC: 11754289. DOI: 10.3389/fphar.2024.1475414.

Investigating the effects of percutaneous endovascular aneurysm repair for abdominal aortic aneurysm on the lumen size of the common femoral artery.

Ong W, Tay H, Chong T CVIR Endovasc. 2024; 7(1):66.

PMID: 39254910 PMC: 11387579. DOI: 10.1186/s42155-024-00476-0.

Does an Aspirin a Day Take the MASLD Away?.

Lonardo A, Zheng M Adv Ther. 2024; 41(7):2559-2575.

PMID: 38748333 DOI: 10.1007/s12325-024-02885-y.

Aspirin for preeclampsia prevention in low- and middle-income countries: mind the gaps.

Kupka E, Roberts J, Mahdy Z, Escudero C, Bergman L, De Oliveira L AJOG Glob Rep. 2024; 4(2):100352.

PMID: 38694484 PMC: 11061325. DOI: 10.1016/j.xagr.2024.100352.

The pharmaco-epigenetics of hypertension: a focus on microRNA.

Yaacoub S, Boudaka A, AlKhatib A, Pintus G, Sahebkar A, Kobeissy F Mol Cell Biochem. 2024; 479(12):3255-3271.

PMID: 38424404 PMC: 11511726. DOI: 10.1007/s11010-024-04947-9.

References

Gong Y, Lin M, Piao L, Li X, Yang F, Zhang J . Aspirin enhances protective effect of fish oil against thrombosis and injury-induced vascular remodelling. Br J Pharmacol. 2014; 172(23):5647-60. PMC: 4667862. DOI: 10.1111/bph.12986. View

Bots M, Ford I, Lloyd S, Laurent S, Touboul P, Hennerici M . Thromboxane prostaglandin receptor antagonist and carotid atherosclerosis progression in patients with cerebrovascular disease of ischemic origin: a randomized controlled trial. Stroke. 2014; 45(8):2348-53. DOI: 10.1161/STROKEAHA.114.004775. View

Zhou Y, Luo W, Zhang Y, Li H, Huang D, Liu B . Cyclo-oxygenase-1 or -2-mediated metabolism of arachidonic acid in endothelium-dependent contraction of mouse arteries. Exp Physiol. 2013; 98(7):1225-34. DOI: 10.1113/expphysiol.2013.072017. View

Hermida R, Ayala D, Calvo C, Lopez J . Aspirin administered at bedtime, but not on awakening, has an effect on ambulatory blood pressure in hypertensive patients. J Am Coll Cardiol. 2005; 46(6):975-83. DOI: 10.1016/j.jacc.2004.08.071. View

Dai S, Li W, Li G, Huang J . Proteome-wide prediction of targets for aspirin: new insight into the molecular mechanism of aspirin. PeerJ. 2016; 4:e1791. PMC: 4793309. DOI: 10.7717/peerj.1791. View

De Miguel C, Rudemiller N, Abais J, Mattson D . Inflammation and hypertension: new understandings and potential therapeutic targets. Curr Hypertens Rep. 2014; 17(1):507. PMC: 4418473. DOI: 10.1007/s11906-014-0507-z. View

Rainger G, Chimen M, Harrison M, Yates C, Harrison P, Watson S . The role of platelets in the recruitment of leukocytes during vascular disease. Platelets. 2015; 26(6):507-20. PMC: 4673595. DOI: 10.3109/09537104.2015.1064881. View

Ho K, Spite M, Owens C, Lancero H, Kroemer A, Pande R . Aspirin-triggered lipoxin and resolvin E1 modulate vascular smooth muscle phenotype and correlate with peripheral atherosclerosis. Am J Pathol. 2010; 177(4):2116-23. PMC: 2947304. DOI: 10.2353/ajpath.2010.091082. View

Brandes R . Endothelial dysfunction and hypertension. Hypertension. 2014; 64(5):924-8. DOI: 10.1161/HYPERTENSIONAHA.114.03575. View

10.

Karmohapatra S, Chakraborty K, Kahn N, Sinha A . The role of nitric oxide in aspirin induced thrombolysis in vitro and the purification of aspirin activated nitric oxide synthase from human blood platelets. Am J Hematol. 2007; 82(11):986-95. DOI: 10.1002/ajh.20955. View

11.

Mancia G, Zanchetti A, Bohm M, Christiaens T, Cifkova R, De Backer G . 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2013; 34(28):2159-219. DOI: 10.1093/eurheartj/eht151. View

12.

Zhang M, Song P, Xu J, Zou M . Activation of NAD(P)H oxidases by thromboxane A2 receptor uncouples endothelial nitric oxide synthase. Arterioscler Thromb Vasc Biol. 2010; 31(1):125-32. PMC: 3005129. DOI: 10.1161/ATVBAHA.110.207712. View

13.

Vital S, Becker F, Holloway P, Russell J, Perretti M, Granger D . Formyl-Peptide Receptor 2/3/Lipoxin A4 Receptor Regulates Neutrophil-Platelet Aggregation and Attenuates Cerebral Inflammation: Impact for Therapy in Cardiovascular Disease. Circulation. 2016; 133(22):2169-79. PMC: 4889496. DOI: 10.1161/CIRCULATIONAHA.115.020633. View

14.

Ayala D, Hermida R . Sex differences in the administration-time-dependent effects of low-dose aspirin on ambulatory blood pressure in hypertensive subjects. Chronobiol Int. 2010; 27(2):345-62. DOI: 10.3109/07420521003624662. View

15.

Schildknecht S, van der Loo B, Weber K, Tiefenthaler K, Daiber A, Bachschmid M . Endogenous peroxynitrite modulates PGHS-1-dependent thromboxane A2 formation and aggregation in human platelets. Free Radic Biol Med. 2008; 45(4):512-20. DOI: 10.1016/j.freeradbiomed.2008.04.042. View

16.

Raju N, Sobieraj-Teague M, Hirsh J, ODonnell M, Eikelboom J . Effect of aspirin on mortality in the primary prevention of cardiovascular disease. Am J Med. 2011; 124(7):621-9. DOI: 10.1016/j.amjmed.2011.01.018. View

17.

Petrucci G, Rizzi A, Cavalca V, Habib A, Pitocco D, Veglia F . Patient-independent variables affecting the assessment of aspirin responsiveness by serum thromboxane measurement. Thromb Haemost. 2016; 116(5):891-896. DOI: 10.1160/TH16-05-0349. View

18.

White S, Newby A, Johnson T . Endothelial erosion of plaques as a substrate for coronary thrombosis. Thromb Haemost. 2016; 115(3):509-19. DOI: 10.1160/TH15-09-0765. View

19.

Higashi Y, Maruhashi T, Noma K, Kihara Y . Oxidative stress and endothelial dysfunction: clinical evidence and therapeutic implications. Trends Cardiovasc Med. 2013; 24(4):165-9. DOI: 10.1016/j.tcm.2013.12.001. View

20.

Lassegue B, San Martin A, Griendling K . Biochemistry, physiology, and pathophysiology of NADPH oxidases in the cardiovascular system. Circ Res. 2012; 110(10):1364-90. PMC: 3365576. DOI: 10.1161/CIRCRESAHA.111.243972. View